Canaccord Genuity analyst Whitney Ijem maintains Wave Life Sciences (NASDAQ:WVE) with a Buy and r

Oppenheimer analyst Cheng Li maintains Wave Life Sciences (NASDAQ:WVE) with a Outperform and lowe

Wave Life Sciences, Inc. (WVE) Q3 2026 Earnings Call Transcript

WAVE Life Sciences NASDAQ: WVE reported higher third-quarter revenue and a wider net loss as it incr

Wave Life Sciences (WVE) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus

Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.30) per share which beat the analys

Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysi

WAVE Life Sciences NASDAQ: WVE outlined progress across its obesity-focused siRNA program and RNA ed

CAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinic

CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinic

William Blair analyst Alethia Young initiates coverage on Wave Life Sciences (NASDAQ:WVE) with a

UBS analyst Joon Lee initiates coverage on Wave Life Sciences (NASDAQ:WVE) with a Buy rating and

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinic

WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report)'s share price reached a new 52-week low duri

WAVE Life Sciences (NASDAQ: WVE - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Fre

Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) rose 9.3% on Thursday. The company

Shares of WAVE Life Sciences Ltd. (NASDAQ: WVE - Get Free Report) gapped up before the market opened

Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking

Following meeting with FDA, Wave plans for a single, two-year registrational trial, with a one-year

Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and

Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone

Analysts downgraded Ryder, Warner Bros. Discovery, Arbor Realty, Pershing Square and PepsiCo; Ryder

Analysts downgraded PepsiCo, RLJ Lodging Trust, Braskem.

RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance inn

Analysts downgraded Nike, Comcast, Restaurant Brands.

Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; pric

Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking th

WVE-007 induces fat loss without muscle loss, with clinical data supporting 1-2x per year dosing; pr

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Bl

Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth qu

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers

Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe

B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy

Wedbush analyst Yun Zhong maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.34) per share which missed the anal

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmf

Wells Fargo analyst Benjamin Burnett maintains WAVE Life Sciences (NASDAQ:WVE) with a Overweight

HC Wainwright & Co. analyst Andrew S. Fein maintains WAVE Life Sciences (NASDAQ:WVE) with a B

Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a

Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowe

Canaccord Genuity analyst Whitney Ijem maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and l

Truist Securities analyst Danielle Brill maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and

Top Wall Street analysts have changed their outlook on top names. For full analyst rating changes, i

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen